Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease

NCT02954978 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

75

Enrollment

OTHER

Sponsor class

Conditions

Parkinson Disease
Parkinsons Disease With Dementia

Interventions

DRUG: Placebo Oral Capsule
DRUG: Nilotinib 150mg oral capsule [Tasigna]
DRUG: Nilotinib 300mg oral capsule [Tasigna]

Sponsor

Georgetown University